Good day, and thank you for standing by. Welcome to the Indivior Q3 2024 update. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star one and one on your telephone. You'll then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised today's conference is being recorded. I'd now like to hand the conference over to your host for today's call, Jason Thompson. Please go ahead. Thank you, Sarah, and good morning and afternoon, everyone. Before we begin, I need to remind everyone that on today's call, we may make forward-looking statements that are subject to risks and uncertainties, and that actual results may differ materially. We list those factors on page four of this morning's announcement that is available on our website at www.indivior.com. Finally, given where we are in the quarter and close process, we ask that you limit your questions to the matters discussed in today's announcement. We will address third quarter results and broader Q&A at our formal results. With that, I will turn the call over to Mark Crossley, our CEO. Thanks, Jason, and good morning and good afternoon, everyone. Thanks for joining us on short notice. Ryan Preblick, our CFO, is also joining us here today. I'm sure by now that you've read the announcement, where we've described the challenging market dynamics that we've been navigating, which have adversely impacted our near-term financial performance and outlook. Let me walk you through the highlights. For our revised near-term outlook, we've seen several external factors combine to create lower net revenue visibility and greater than expected initial adoption of the competitor product. First, we have seen increased competitive pace and intensity. Our competition is gaining initial adoption among SUBLOCADE incumbent prescribers faster than our expectations. In addition, in the criminal justice system channel, we're experiencing both increased competitive pressure, including modest pricing pressure, as well as more unpredictable volumes due to funding variability in some accounts. Recall, this channel is largely dependent upon government funding, including grants and legislative allocations to fund patient treatment. In some activated accounts, incremental SUBLOCADE volume is pending this funding, while in others, strong continued SUBLOCADE uptake has exceeded designated budgets, resulting in temporary treatment lapses. As a result, while our CJS business grew strongly year- over- year, we're expecting to see a sequential net revenue decline in this channel in the third quarter because of these two issues. That said, among our CJS accounts, we continue to see great interest and intention to treat with SUBLOCADE, and therefore, we continue to expect strong contribution to SUBLOCADE growth from this channel in the long term. Lastly, we're seeing increased one-off impacts from additional destocking in the quarter, and that's in addition to the dynamics we spoke with the Q2 update. These factors have combined to make SUBLOCADE net revenue forecasting accuracy difficult in the near term. In light of recent developments, we've incorporated our learnings and updated our fiscal year 2024 guidance. We believe this new net revenue guidance for SUBLOCADE is achievable, and we still expect to show solid year-over-year growth for SUBLOCADE in fiscal year 2024 of 17% at the midpoint. However, as you'd expect, we're actively seeking efficiencies to accelerate this growth and support margins. Looking further out, we now expect a period of slower growth for SUBLOCADE in the near term, as the market adjusts to two players in the long-acting injectable category. This expected slower growth period means we no longer expect to deliver a billion-dollar annual net revenue run rate for SUBLOCADE exiting 2025. Simply, the competitor's growth from initial HCP adoption will largely come at the expense of SUBLOCADE. We continue to believe that SUBLOCADE has a greater than $1.5 billion peak net revenue potential, and despite competitive inroads and temporarily lowered growth profile, we're seeing strong evidence that SUBLOCADE is sustaining its leadership position in the category. We've been tracking multiple market cohorts since the competitor's launch a year ago, and while we have seen faster than expected initial adoption, recent market data is consistently showing that SUBLOCADE's share is stabilizing over the past four months at levels demonstrating its leading position in the clinic. If maintained at these levels, it confirms our belief that SUBLOCADE's unique product profile will lead to its continued leadership role in the long-acting injectable category. When we look further out at the potential for long-acting injectables overall, we believe there remains huge scope for increased market penetration and growth. HCP research continues to suggest approximately 30% of patients in their practices will be treated with a long-acting injectable. Recent data shows the share of LAIs as a portion of medically- assisted treatment, buprenorphine medically- assisted treatment, is approximately 7%, with SUBLOCADE garnering most of the share. We obviously hope for better recent performance and are taking several measures to ensure we maintain SUBLOCADE's leading position among long-acting injectable prescribers. First, our Chief Commercial Officer, Richard Simkin, has taken on direct leadership of day-to-day operations of SUBLOCADE in the United States. Second, we expect to improve SUBLOCADE's patient experience through important label updates. As you will have seen on Monday, we were granted priority review by the FDA for these updates, which includes alternate injection sites for SUBLOCADE induction and maintenance, as well as the ability to rapidly induce a patient on SUBLOCADE after a single dose of transmucosal buprenorphine. In fact, if approved, SUBLOCADE will be the only monthly injectable approved for rapid induction for OUD patients. We expect these elements to be incorporated into SUBLOCADE's U.S. label in February, and based upon research and anecdotal feedback, we expect this to be strongly received by both treatment providers and patients. As a reminder, we recently updated the label to allow for storage of SUBLOCADE at room temperature for up to 12 weeks, and this product is already in the market. Third, as I previously indicated, we're actively seeking efficiencies to fuel SUBLOCADE's growth and support margins. More specifically, we'll look to increase investment behind SUBLOCADE awareness, as well as general awareness of long-acting injectables, as our research shows that treatment awareness among OUD patients remains low. Less than 15% of patients are aware of any brand name in the category. These initiatives will complement the sales force and Justice team expansion we completed earlier this year, where we continue to see increased productivity. Our increased call frequency and productivity has yielded approximately 120 new Justice entities this year through the second quarter, and we're seeing expansion in the number of patients they treat each month. Additionally, growth in new prescribing HCP. It also is continuing, with an absolute increase in treatment providers year- over- year. In closing, while we face greater near-term competitive and market headwinds than we had predicted, we remain firm in our conviction that SUBLOCADE has the ideal profile to meet the needs of patients. SUBLOCADE attains therapeutic levels of dosing in four- eight hours and maintains dosing levels the entire month after one shot. We do not believe that any other long-acting injectable achieves that during the dosing period, and this is playing out in the cohorts of early competitor adopters, where we're seeing SUBLOCADE's leading share stabilize over the last three- four months, and of course, the disease space continues to have a tremendous unmet need, with eight of 10 patients not in treatment. Taken together, this gives us confidence in the long-term net revenue opportunity we see for SUBLOCADE of greater than $1.5 billion. In sum, we're still nearer the beginning of the journey than the end, and we remain excited about the potential for SUBLOCADE. With that overview, I'll turn over to questions and answers. Sarah? Thank you. If you would like to ask a question, you'll need to press star one and one on your telephone and wait for your name to be announced. And to withdraw your question, please press star one and one again. Thank you. We'll now take our first question. This is from the line of James Vane-Tempest from Jefferies. Please go ahead. Hi, thanks for taking my questions. A couple, please. Firstly, given we had a profit warning in the summer, and now we've had another one, what confidence can you give us that, I guess, there's not going to be a third profit warning? And also on the $1.5 billion peak revenue number, and if we should be thinking that's gonna be achievable at a later date now. And then my second question is, you talk about slower growth for SUBLOCADE in the near term, but how should we think about the level of investment here? So with more competition, should we be thinking accelerating SG&A next year, or what you need to do to defend your market position? Thank you. Thanks for that, those questions, James. Listen, I think as we think about, you know, the volatility, you know, that we've seen in this market, you know, what we've seen is really a confluence of events, intensified competition, short-term funding fluctuations and certain CJS accounts and stocking levels below, you know, previously reduced amounts. I think as we've taken the learnings that we've gotten from those three elements and incorporated those into this guidance, you know, it gives us confidence that we've set a guidance that we can achieve in the balance to go. So we have good conviction in that number. On the greater than $1.5 billion peak net revenue guidance, you know, we've never guided timing on that, but these initial cohorts, you know, the in-market data, you know, that we're seeing, you know, with regards to breakthrough, and the lack of hold of the competitive product, and the fact that physicians believe efficacy is the number one thing driving their decision, give us, you know, increased conviction behind that greater than $1.5 billion. When we think about next year's profile, listen, I think we'll guide on fiscal year 2025 when we get to the February fiscal year end. I think, you know, as we think about, you know, our capital allocation, we'll be actively managing that capital allocation with a focus on both fueling growth and preserving margins. Thank you. Thank you. We'll now move to our next question. This is from the line of Chase Knickerbocker from Craig-Hallum. Please go ahead. Morning, guys. Thanks for taking the questions. So if, if we kind of look at what guidance range assumes for, for Q4, it kind of assumes kind of a, a 9% kind of sequential decline. If... Should we think of any kind of headwinds as kind of one-timey in Q4, or should we be kind of thinking about this being, you know, kind of the, the new normal as far as what the competitive environment is at this point? And then can you kind of talk us through the split of what kind of drives that SUBLOCADE, kind of decline sequentially more? So is it CJS, competition in CJS, or is it, on the direct prescriber side? And then kind of can you walk us through some of your assumptions as far as kind of what that assumes from kind of new patient share that your competitor is taking? Thank you. Maybe I'll start with the last one and then head into the items with regards to the Q4 dynamics, Chase. I think, listen, we're still seeing, you know, in line with the dynamics we saw at the half year, where the predominant amount of new patient share is still coming to SUBLOCADE. You know, which is encouraging, and you combine that with the cohort data, and it just further supports, you know, SUBLOCADE's role here and eventual share leadership as the market stabilizes out. As we look to the Q4 guide, really, you know, with the three drivers that we had, I would say the predominant two drivers were the accelerated competition with their accelerated initial adoption, and the dynamics in CJS, with a bit of increased competition and the funding dynamics, which are exacerbated as we approach fiscal year-end for both the federal and state entities. You know, I would say we probably have built in about $10 million or so of continued stocking dynamics, and then the balance of that is equally split, you know, between the other two dynamics. Got it. And then just, specifically on the criminal justice side, you know, is it safe to assume that in Q4, that kind of shortfall there is mainly the competitive conversions rather than, you know, the, the funding headwinds? And then kind of how do you think about your profile there relative to your competitor, as they, you know, obviously look to take additional share there? And then just last from me, when we think about what kind of helps you stabilize kind of the share in the market here, do you think kind of all that's required is that, you know, kind of February PDUFA with those last two remaining product profile items? Or what are you hearing from your customers as far as what's driving increased sampling? Thank you. So a lot to unpack there. Let me, let me maybe get into there. When we think about the CJS dynamic, listen, I think it's, it's a combination of both. We had competition, you know, and, and we shared this at earlier conferences because it was in the IQVIA data, where they got access to, to a large account on the West Coast that we had not factored in. And we're seeing this funding issues that are exacerbated, you know, the federal sort of fiscal year-end is, you know, the end of September, and then many of the states are at the end of the year, and this ramp-up in adoption bumps up against their budgets. We see this as a transient sort of issue as they increase their budgets, get more grants, and the flow of funds down into this very critical treatment area, so you know, we'll see some lumpiness as this goes, as adopters come in, and they've got an in-year budget during their period of adoption, but we'll work our way through that as they get additional funding. As we look towards the profile in criminal justice, I think it's similar to outside the walls. You know, when you're looking at what would be the more normal sort of treatment arena, you know, these criminal justice systems, you know, are looking for something that they can reduce their overall use of resources and will keep these patients, you know, with therapeutic doses the entire month long. So we see SUBLOCADE, you know, playing a greater role in the justice system versus competition. As we look to stabilization, listen, I think there is just gonna be a transition period here that's gonna lead to, you know, a bit of slower growth as the competitor product continues to get initial adoption. You know, and that transition period will lead to the slower growth. I think that there will be some elements as we continue to focus on awareness, you know, disease-based stuff, and take away some of the features, you know, that are differentiated versus competition, like the alternate sites of injection, like rapid induction, and create some additional benefits and differentiation for us. Like, we will be the only monthly with rapid induction, which is a significant benefit in CJS, you know, because you'll have less resource utilization than doing, you know, weekly doses. So we see those as help, but we think there will be a transition period while the competition continues to get adoption. But remember those cohorts, Chase. I think the key here is that when we look at those cohorts, they stabilize out, you know, and— over about a year period, and we see over three- four months that they stabilize with us in share leadership. Thanks, Mark. Thank you. We'll now take our next question. This is from the line of Paul Cuddon from Deutsche Numis. Please go ahead. Hi there, guys. Thank you. I've got two questions please. I mean, firstly, you've not mentioned Medicaid disenrollments in this particular kind of update. So I'm just wondering if you could give us a bit of an update on the state of play there. And then secondly, just on the kind of potential of both products to be expanding the market into patients that are not currently treated, I mean, would you kind of conclude that the competitor weekly product has not been successful in expanding the market? That if you were able to offer rapid induction and multi-site injection, that would be a game changer for the broader patient populations that are not currently seeking treatment. You were breaking up there a little bit, Paul, but I think I got both of your questions. We haven't mentioned the Medicaid disenrollments because they continue as we built into our guidance, our last guidance update. So the dynamics haven't changed. You know, we still are through the vast majority of those, with one more state expected to disenroll by November. And then, you know, three more states left, you know, for next year. So the dynamics are as expected, and we expect those to be heading into 2025. When it comes to expanding the market, I think this is a result of, you know, the competition has commercially focused on initiating trial in LAI adopters and key accounts that have taken LAIs into their patient thesis. So we're the only people out there that are focused on actually growing the market. And the market, you know, it has enabled us to grow 17% year- over- year, but we haven't grown as fast as we want because of the cannibalization associated with the accelerated adoption. When we think about moving forward, we expect as the market stabilizes, that share of voice from having two, two LAI products as well as two sales forces out there, will start to accelerate growth in the market, you know, once the market stabilizes out. Last question on pricing. Is this something we should be assuming is under a bit of pressure on price per dose in the future, or is that not an issue? Yeah, listen, overall, as I've, as I've kind of mentioned, pricing is constructive, and there's open access, you know, across the category that allows patients and HCPs to make the decision for the product that's best for them. Sometimes they believe that's an oral and then, and then long-actings. We have seen the competition use price as a tool in select justice system accounts, and believe that's, that's how they won the account we spoke about on the West Coast, where price sensitivity, given some of the funding sources, you know, are dependent on grants and legislative actions. You know, to be clear, you know, we're prepared to take appropriate steps to defend our business, you know, that we believe are in the best interest of the therapy area. So, you know, we think of equal price and then enabling choice. And for us, we believe when there's free choice, SUBLOCADE will continue to hold the number one position, you know, as we've talked with regards to the dynamics on the cohorts, efficacy as the number one value item. So, hope that provides the context you're looking for. Okay. And then just one final one, just on the buyback, that's continuing. You've not put it in the statement. No, that's continuing. That launched in August, and as we mentioned, well, we plan on having that have a duration of six months. Okay, super. Thank you very much. Thank you, Paul. Thank you. We'll now take our next question. This is from David Amsellem from Piper Sandler. Please go ahead. I have three questions. Number one, can you talk to the extent to which the smaller needle size associated with BRIXADI is hurting your business? Secondly, can you talk to where you think your share of new starts is going to settle out as you get through this transition period from being the only game in town to now being part of a two-player market? And then lastly, given all of the different moving parts that conspired to result in a couple of times of lowered guidance, how are you thinking about 2025, and can you give us at least a roadmap as to what conservative, achievable expectations for 2025 would look like? Or maybe I'll ask it a different way. What have you learned from the 2024 experience? Thanks. Thanks for those, David. Listen, with regards to the smaller needle, you know, I think this is certainly a feature, and I think it's used and sounds good in the experience with the patient. When you look to the phase III studies for both of our products, you know, there's similar adverse event percentages. I think we were 8.7%, they were just over 9% with regards to pain of injection. And, you know, we've hypothesized that that's because of the buprenorphine coming in contact with the [sub-Q]. So we don't see pain as a major differentiation. I think there's some features there that should win out with efficacy. We believe that the alternate injection sites will take some of that issue with the larger needle away because you won't be injecting in the abdomen and there won't be as much of a visual reinforcement in that. So we think that new label change that should come in February will certainly be helpful with regards to that experience and that feature benefit that the competition has with the smaller needle. With regards to new starts with two players, I think the key here is where will this end up? I think we have to look to the cohorts data, you know, with where the market is ending up with these early adopters, the people that, you know, you would have said are into the new technology, they're adopting the new technology, or they have a strong belief in, you know, the concept that surrounds the competition that led to that early adoption. And what we see with those cohorts is that we have strong share leadership, as they settle out, and we've seen good stabilization over three- four months that reinforce, you know, that belief on strong leadership for SUBLOCADE. David, I respect the question with regards to the moving pieces that will... that, you know, and where do we get to with where guidance will be for 2025, but I think that's for us to give with the fiscal year-end results. I think we've talked about a continued transition period as the market adjusts to two players and the, you know, accelerated adoption of the competitor as that comes through, the fact that they're focusing on heavy SUBLOCADE users or key accounts and not focused on growing the market. So we expect that cannibalization to continue. But oddly, the fact that it's accelerated actually is in some odd ways, it's a positive because the market should stabilize out sooner and we can get to a growing market helping patients, you know, and we believe, you know, with that, that SUBLOCADE, you know, will be the leader in this space. Thank you. Thank you. We'll now move to our next question. This is from Thibault Boutherin from Morgan Stanley. Please go ahead. Thank you. First question from me is on the market share you mentioned in the early cohorts. When you're monitoring things here, are you seeing initially a swing in favor of BRIXADI and then the share coming back to SUBLOCADE as maybe these solutions are experiencing the breakthrough issue or you know, once they've done kind of experimenting with BRIXADI, they come back to SUBLOCADE? So just you know, see if you if you're seeing this sort of market share swing. Second question is just you mentioned the kind of three, four months to get to this stable market share in these early cohorts. How does that translate into the broader patient population? Because if it's three, four months, it should be relatively quick to get to kind of you know, stable market share in the market. So clearly, your guidance assumes Q4 is going to see headwinds. So when do you think the trough is? Is it Q4? Could Q1 next year still, you know, be challenged and go through this? Basically, when, you know, when do you expect to see SUBLOCADE, you know, turning to growth? Maybe starting there and another follow-up on the CJS. Certainly. I think those cohorts, I appreciate the question there, Thibault, and I think with the shape of those, you know, yes, you do see them go up, and they come and they do even come back down. But throughout the entire shape of the curve, as we look at these, you know, SUBLOCADE is maintaining, you know, strong share leadership, which is good for us, that we do see the shape come back down near the end. I just to clarify my position with regards to the stabilization, those early cohorts that would have started a year ago, 11 months ago, you know, 10 months ago, they're stabilizing now over the last three- four months. So it takes time once people try and they adopt, and remember, these are the you know the early innovators that are adopting, that we're analyzing, you know, it takes time for those to stabilize out. So we, you know, as we look at timing, you know, that's gonna be, you know, the one moving forward with regards to how long that transition period will be with the next wave of adopters, how long it takes for them to get that penetration, get the adoption in the market to stabilize out. But we expect that to happen, and in the medium to long term, you know, we fulsomely believe that SUBLOCADE's growth thesis is completely intact and stand behind, you know, the greater than $1.5 billion peak in net revenue. Thank you for the clarification. And just the last one on the criminal justice system. Could you just help us understand what is the process here in terms of kind of winning, losing accounts, how dynamic these accounts are? You know, is it, is it a tender system, you know, is it committed volumes? If you could just help us understand the how, you know, how it works. Yeah, I, I wish there was a standard system for this that I could share, Thibault, but it really, it really is jail system to system, you know, depending on how they're dealing with it. You know, some are, some are binary, only one, one product. Some have both and, and have utilization across, and it just varies, product to product with regards to that. I think, you know, for us, the key is, is what's needed to be successful in a justice system? One, you know, they're worried about resource utilization and liability, and having less doses is important to them. You know, you know, and then two, you know, they want those, those patients to be stabilized all month long, because if there's breakthrough earlier, they're gonna have to come back for additional treatment or oral doses or things of that nature. So we see those as the primary drivers, and there's, as we talked, you know, there's always a bit of a cost sensitivity there. But we, again, we believe in let's get, you know, our costs in line and then, you know, let the systems choose which product they want to use. Thank you. Thank you. We'll now take our next question. This is from Christian Glennie from Stifel. Please go ahead. Hi, guys, thanks for taking the questions. Apologies if I missed this earlier. Just on your market share of new patients, I think you said you had the dominant share. But could you be more specific around that? I think previously you were around sort of 70%, 80% of new patient starts, but what that level would be today? And then just maybe I can push you again, maybe a bit more on the 2025 guide in terms of directional here. You know, are we potentially in a decline in 2025 or flat or a bit of growth? You know, my thinking here is we'll probably have some Q1 and Q2, maybe some continuing decline trends, but a recovery in the second part of the year gets you to flat. Just anything a bit more directionally on 2025, please. Thanks, Christian, for the question. I think. Listen, we haven't closed out the quarter and have the data with a lag with regards to the new patient share, so I think we're gonna hold off on the specificity of with regards to that. But we haven't seen material changes, at least in some of the initial data throughout the quarter versus what we talked at the half year. Again, with regards to the 2025 guide, I think, you know, I've been about as specific as I can be with regards to the forces and the transition period as we look to next year. You know, and what we'll do is we'll guide on that, you know, in February with regards to where we see, you know, SUBLOCADE and the overall company net revenue projections next year. Okay. Thank you, and then a follow-up, if I can. Just a reflection, maybe, you know, splitting out the sort of moving parts versus, you know, where you are today versus where you started the year, just to get the sort of relative weightings in terms of the impacts of the various things through the year, if you can. You know, starting the year at midpoint 35% guide, and now the 17% today for the midpoint. Yeah, the various dynamics that you've talked about through the year, just you know, either apportion them to the different factors here, please. Yeah, I think, listen, it has been a confluence of many events that have hit this year and provided, you know, significant volatility. You know, I think if we think through the factors of the transitory items like the Medicaid renewal, the Change Healthcare, you know, and the stocking dynamics, which we expect to stabilize out, and as we enter next year, you know, get to, you know, more of the CJS, and or the competitive environment and sort of CJS funding and making certain we incorporate those into our forecasting. Taking the learnings we have, you know, to make certain, you know, we're able to accurately guide the market moving forward. And in addition, you know, take those learnings that we have, you know, and speak to the additional conviction it provides with regards to the growth thesis on SUBLOCADE in, in the medium and the long term. Because, you know, again, that stabilizing of those cohorts, you know, what we're hearing in the market with regards to breakthrough and, and lack of hold, you know, I mean, for physicians today with high-powered synthetic opioids, if a patient relapses from, from treatment, they're a potential overdose victim. And so I think that's just coming to the forefront, and we see that in the, in the HCP research that says efficacy is their number one, you know, force on their choice of what they're going to use. Okay. Thank you. Thank you, Christian. Thank you. We have a follow-up question coming through. Please stand by. This question is from the line of Paul Cuddon from Deutsche Numis. Please go ahead. Thank you, guys, for taking my follow-up. Just wondering, on how you're thinking of the cost base heading into FY 2025 as well. I mean, the SG&A line and the R&D line are quite something, and you've hinted at efficiencies, but to what extent should we think about the ability to realize those? I don't want to get into a tremendous amount of detail, but I think we can rest assured that we're actively assessing our capital allocation, you know, with a focus on both growth of SUBLOCADE as well as supporting margins. You know, I think we've shown a willingness to make tough choices in the past. Think about recent, even recent decisions on PERSERIS, on stopping ALS development, you know, which all provide flexibility on costs as we enter 2025. We still believe we have a number of other levers, which we, you know, continue to assess, including items such as discretionary spending, capital, and other cash items. We'll look to fuel SUBLOCADE and support margins, you know, through that process. Thank you. Thank you. Thank you. We have another follow-up question coming through. This is from the line of Christian Glennie from Stifel. Please go ahead. Hi, guys. Great. Follow up, please. Just to understand, the things that you have in your toolkit as it relates to sort of, you know, pushing back and competing back against, you know, the competitive headwinds here. Obviously, you've talked about, you know, the profile, SUBLOCADE is a better once monthly, as a pure sort of, you know, education thing, and maybe we'll see, you know, as we see the breakthroughs with the competitor, you know, that will play out more in favor of SUBLOCADE. But specifically anything else around, you know, sales force, sizes maybe, or marketing or anything else that sort of, or price even? I mean, so is there anything else that you're sort of thinking about as your sort of strategy beyond the sort of education around the profile of SUBLOCADE? I think this is an important item, Christian, and I think, you know, part of this having a year with a competitor in the market certainly informs this. And those cohorts where they're stabilizing out, you know, with strong share leadership for SUBLOCADE, you know, certainly inform our beliefs that we have the right product, the right profile, you know, efficacy, in, you know, reinforcing the message on efficacy as the number one factor with physicians. You know, a patient who relapses is a potential overdose victim, and making, you know, certain that that dynamic is heard out there. And then, you know, further reinforcing, you know, the profile of SUBLOCADE. Taking that and then supplementing it with broader patient awareness of both SUBLOCADE and LAIs to drive patients into treatment, we see, we see as a key, and then just continued strong execution by both our, our sales force as well as our criminal justice team. These are the folks on the ground, you know, that are going to continue to drive SUBLOCADE's growth as we get through this transitionary period of this, of this initial adoption, because, you know, as it stabilizes out, there's a tremendous, tremendous opportunity for SUBLOCADE. With regards to price, and I- I'll just reinforce my comment earlier: Listen, we want to take price out of the equation for, for our stakeholders. You know, we believe that this disease space for 20 years has been focused on open access and reducing barriers to treatment and choices across the entire decision set, and we think that's what's right in the best interest of patients and physicians, that they have that choice for the best medication based on where they are in their journey. Thank you. Thank you, Christian. Thank you. We're showing no more questions currently, so I'll turn the call back to you, Mark, for any closing comments. Thank you, Sarah, and thanks everyone for joining on short notice, you know, for this update. We'll speak to you again with our full Q3 results at the end of the month. Thank you. Thank you. This concludes today's conference call. Thank you for participating, and you may now disconnect.